Labcorp Holdings Stock: Analyst Estimates & Ratings

Labcorp Holding Company (LHheadquartered in Burlington, North Carolina, is a leading global provider of comprehensive laboratory services. The company operates across two main segments: diagnostic laboratories and biopharmaceutical laboratory services, offering a wide range of tests, from blood chemistry and microbiology to advanced and esoteric genetic diagnostics. The market capitalization of Labcorp is About $21.7 billion.

The medical laboratory operator’s shares underperformed the broader market. Over the past 52 weeks, LH stock rose 9.9%while the broader Standard & Poor’s 500 index ($sps) has 10.5% profit. However, the stock is up 14% year-over-year since the beginning of the year, compared to the SPX’s 11.2% rise.

Looking more closely, the medical laboratory operator has overtaken its healthcare sector SPDR (Forty-fifth) 6% increase Over the past 52 weeks and 10.1% since the beginning of the year.

LH stock has surged in 2025, driven largely by strong execution in its diagnostics business and bullish investor sentiment. There is a growing demand for high-value specialty tests (oncology, neuroscience, women’s health), thanks to key integration and AI-driven efficiency initiatives.

The company also achieved strong results for the third quarter on October 28 Adjusted EPS of $4.18, up 19.4% from the year-earlier quarter. However, stocks It fell about 5.8% on earnings announcement day And 4.5% the next day. The softer reaction appears to be driven by the fact that despite the earnings beat, the company trimmed its full-year revenue growth guidance to a 7.4% to 8% range, which may have raised investor caution.

For the fiscal year ending December 2025, analysts expect Labcorp Adjusted EPS to grow 12% year over year To $16.32. The company’s surprising earnings history is promising. It has topped consensus estimates for the last four quarters.

Of the 18 analysts covering the stock, Consensus rating It is a “strong buy”. This is based on 14 “Strong Buy” ratings and four “Holds.”

This composition has remained largely constant over the past few months.

This month, JPMorgan analyst Lisa Gill Maintained “overweight” rating. on Labcorp Holdings and raised the price target to $317.

While the average price target of $300.70 suggests 15% upside potential, the Street’s price target of $342 suggests the stock could rise as much as 30.8% from current price levels.

On the date of publication, Sristy Jayaswal had no positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data contained in this article are for informational purposes only. For more information, please see Barchart’s Disclosure policy here.